IMUNON Q2 net loss $2.8M; OVATION 2 shows 14.7-month OS benefit, Phase 3 on track

Imunon, Inc.

Q2 2026 net loss $2.8M ($0.54/share) vs $2.7M ($2.15/share) in Q2 2025; H1 loss $7.1M ($1.38/share).
Cash and equivalents $6.9M at June 30, 2026; operating cash burn $7.0M in H1 2026 vs $5.8M prior year.
OVATION 2 final data: median OS 45.1 vs 30.4 months (14.7-month gain) for IMNN-001+SoC vs SoC alone.
Phase 3 OVATION 3 enrollment exceeds forecasts; DMC recommended continuation; completion expected H1 2029.
Phase 2 MRD data: MRD-positive 44% vs 67%, ctDNA clearance 87.5% vs 62.5%, NED 100% vs 56% for IMNN-001 vs control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.